Welcome to the e-CCO Library!

P489: Clinical experience with ustekinumab in selected Crohn's disease patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Saman*, T. Klag, J. Wendler, M. Goetz, N.P. Malek, J. Wehkamp

Created: Thursday, 21 February 2019, 9:14 AM
P489: Defective anti-microbial peptides expression in Crohn’s disease mucosa can be reversed by strengthening IL-22 signalling
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Fantou*1,2, J. Martin1,2, A. Jarry3, A. Bourreille4,5, R. Josien1,2

Created: Friday, 22 February 2019, 9:41 AM
P489: Double-dose infliximab therapy in Crohn's disease: appropriate time to evaluate the efficacy, long-term efficacy and safety
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kunisaki R., Nishio M., Ogashiwa T., Otake H., Inoue E., Kimura H.

Created: Wednesday, 20 February 2019, 10:36 AM
P489: Predicting mucosal state with faecal calprotectin in children with Crohn’s disease.
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Meglicka*1, M. Szczepanski2, M. Dadalski2, J. Kierkus2

Created: Friday, 22 February 2019, 9:49 AM
P489: Rescue treatment with original versus biosimilar infliximab in biologic-naïve patients with moderate-severe Ulcerative Colitis and corticosteroid failure
Year: 2021
Source: ECCO'21 Virtual
Authors: Muñoz-Villafranca, C.(1);Ogueta, M.Á.(2);Ramírez de la Piscina, P.(2);Álvarez-Herrero, B.(2);Loizate, A.(3);Gómez-Zabala, J.M.(3);De La Maza-Ortiz, S.(1);Aresti, U.(4);Gorostiza, I.(4);Arreba, P.(1);Irigoyen, M.(5);Ortiz de Zárate, J.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P489: Surgery for enterocutaneous fistula: the strongest predictor of postoperative mortality in Crohn's disease patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Iesalnieks, I.(1)*;Adamou, A.(2);Magdalena, B.(2);
Created: Friday, 14 July 2023, 11:05 AM
P489: Temporal trends of colectomy for ulcerative colitis in the multi-drug era; a population based cohort study.
Year: 2022
Source: ECCO'22
Authors: Jenkinson, P.(1);Plevris, N.(1);Lyons, M.(1);Gros, B.(1);Derikx, L.(1);Constantine-Cooke, N.(1);Jones, G.(1);Lees, C.(1);
Created: Friday, 11 February 2022, 3:56 PM
P490 Assessment of body weight changes in patients with inflammatory bowel diseases initiating biologic therapy: A prospective cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Borren, W. Tan, A. Jess, P.H.M. Li, J. Garber, J. Luther, F. Colizzo, H. Khalili, A. Ananthakrishnan

Created: Thursday, 30 January 2020, 10:12 AM
P490: A pilot study of the electronic patient portal “Patient Knows Best” for monitoring biologic therapy in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kamperidis N., O'Connor M., Crook K., Arebi N.

Created: Wednesday, 20 February 2019, 10:36 AM
P490: A vedolizumab population pharmacokinetic model including intravenous and subcutaneous formulations for patients with ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Rosario*1, D. Polhamus2, C. Chen1, W. Sun1, N. Dirks2

Created: Friday, 22 February 2019, 9:41 AM
P490: Clinicians’ adherence to European Crohn’s and Colitis Organisation guidelines in the clinical care of adults with inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

B. Jackson*, D. Con, P. De Cruz

Created: Friday, 22 February 2019, 9:49 AM
P490: Drug survival and immunogenicity after switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: Two-year follow-up of a prospective observational cohort study
Year: 2018
Source: ECCO '18 Vienna
Authors:

L. Smits1*, L. Derikx1,2, A. van Esch1, J. Drenth1, R. Boshuizen3, D. de Jong1, F. Hoentjen1

Created: Thursday, 21 February 2019, 9:14 AM
P490: Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Vermeire, S.(1)*;Peyrin-Biroulet, L.(2,3);Panés, J.(4);Regueiro, M.(5);Kotze, P.G.(6);Charabaty, A.(7);Goetsch, M.(8);Shan, K.(9);Wu, J.(10);McDonnell, A.(11);Woolcott, J.(12);Danese, S.(13);
Created: Friday, 14 July 2023, 11:05 AM
P490: Patients with inflammatory bowel disease should be vaccinated against pneumococcus and influenza despite immunosuppressive therapy
Year: 2022
Source: ECCO'22
Authors: Dohos, D.(1);Müller, K.E.(1);Sipos, Z.(2);Kiss, S.(2);Dembrovszky, F.(2);Kovács, N.(2);Solymár, M.(2);Erőss, B.(2);Hegyi, P.(2);Sarlós, P.(3);
Created: Friday, 11 February 2022, 3:56 PM
P490: The impact of the COVID-19 pandemic on gastroenterologists providing care to inflammatory bowel disease patients in Canada: preliminary data of a cross-sectional survey
Year: 2021
Source: ECCO'21 Virtual
Authors: Mikail, M.(1);Malhi, G.(1);Wilson, A.(2);Khanna, R.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P491 De-escalation of dose-intensified anti-TNF therapy in IBD patients in sustained deep remission
Year: 2020
Source:

ECCO'20 Vienna

Authors:

I. Chu1,2, R. Little1,2, M. Sparrow1,2, M. Ward1,2

Created: Thursday, 30 January 2020, 10:12 AM
P491: Comparison of the durability of response to subcutaneous anti-TNF therapy between ulcerative colitis and Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Mellotte G.*1,2, McShane C.1,2, O'Connell J.1,2, Mc Kiernan S.1,2, Mac Carthy F.1,2, Kevans D.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P491: Efficacy and safety of upadacitinib for the treatment of fistulas and fissures in patients with Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Colombel, J.F.(1)*;Irving, P.(2);Rieder, F.(3);Panaccione, R.(4);Schwartz, D.(5);Hayashi, R.(6);Zhu, X.(7);Lacerda, A.P.(8);Dubcenco, E.(8);Marced, E.(8);Hecht, P.(8);Feng, T.(8);Berg, S.(8);Reinisch, W.(9);
Created: Friday, 14 July 2023, 11:05 AM
P491: Efficacy and safety outcomes of long-term treatment with filgotinib 200 mg among patients with Ulcerative Colitis: An interim analysis of SELECTIONLTE
Year: 2022
Source: ECCO'22
Authors: FeaganSenior Scientific Officer, B.G.(1,2);Matsuoka, K.(3);Rogler, G.(4);Faes, M.(5);Oortwijn, A.(6);de Haas, A.(6);Rudolph, C.(6);Patel, H.(5);Peyrin-Biroulet, L.(7);
Created: Friday, 11 February 2022, 3:56 PM